Cardiac amyloidosis: An update on diagnosis and treatment

Cleveland Clinic Journal of Medicine

Volumn 84, Issue , 2017, Pages 12-26

  Donnelly, Joseph P ^a   Hanna, Mazen ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAMILIAL AMYLOID POLYNEUROPATHY; HEART DISEASE; HUMAN;

AMYLOID NEUROPATHIES, FAMILIAL; HEART DISEASES; HUMANS;

EID: 85046451821     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/CCJM.84.S3.02     Document Type: Article

References (86)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349:583-596
2. Richards DB, Cookson LM, Berges AC, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med 2015; 373:1106-1114
3. Sipe JD, Benson MD, Buxbaum JN, et al. Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 2014; 21:221-224
4. Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol 2015; 24:343-350
5. Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992; 79:1817-1822
6. Krsnik I, Cabero M, Morillo D, et al. Light chain amyloidosis: Experience in a tertiary hospital: 2005-2013. Rev Clin Esp 2015; 215:1-8
7. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998; 91:141-157
8. Sperry BW, Ikram A, Hachamovitch R, et al. Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure. J Am Coll Cardiol 2016; 67:2941-2948
9. Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 2017; Oct 18. [Epub ahead of print] doi:10.1093/eurheartj/ehx589
10. Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 2008; 40:232-239
11. González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015; 36:2585-2594
12. Longhi S, Lorenzini M, Gagliardi C, et al. Coexistence of degenerative aortic stenosis and wild-type transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2016;9:325-327
13. Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 2016; 68:1014-1020
14. Gioeva Z, Urban P, Meliss RR, et al. ATTR amyloid in the carpal tunnel ligament is frequently of wildtype transthyretin origin. Amyloid 2013; 20:1-6
15. Yanagisawa A, Ueda M, Sueyoshi T, et al. Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis. Mod Pathol 2015; 28:201-207
16. Siddiqi OK, Ruberg FL. Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med 2017; Jul 13 [Epub ahead of print] doi:10.1016/j.tcm.2017.07.004
17. Nakagawa M, Sekijima Y, Yazaki M, et al. Carpal tunnel syndrome: A common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. Amyloid 2016; 23:58-63
18. Sekijima Y, Yoshida K, Tokuda T, Ikeda S-I. Familial Transthyretin Amyloidosis. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. Seattle, WA: University of Washington, Seattle; 1993-2017. Available at: https://www-ncbi-nlm-nih-gov.ccmain.ohionet.org/books/NBK1194/. Updated January 26, 2012. Accessed November 16, 2017
19. Buxbaum J, Jacobson DR, Tagoe C, et al. Transthyretin V122I in African Americans with congestive heart failure. J Am Coll Cardiol 2006; 47:1724-1725
20. Ruberg FL, Maurer MS, Judge DP, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J 2012; 164:222-228.e1
21. Wright JR, Calkins E. Amyloid in the aged heart: frequency and clinical significance. J Am Geriatr Soc 1975; 23:97-103
22. Vermeer AMC, Janssen A, Boorsma PC, Mannens MMAM, Wilde AAM, Christiaans I. Transthyretin amyloidosis: a phenocopy of hypertrophic cardiomyopathy. Amyloid 2017; 24:87-91
23. Velazquez-Ceceña JL, Lubell DL, Nagajothi N, Al-Masri H, Siddiqui M, Khosla S. Syncope cardiomyopathy in a patient with primary AL-type amyloid heart disease. Tex Heart Inst J 2009; 36:50-54
24. Stegman BM, Kwon D, Rodriguez ER, Hanna M, Cho L. Left ventricular hypertrophy in a runner: things are not always what they seem. Circulation 2014; 130:590-592
25. Ardehali H, Qasim A, Cappola T, et al. Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J 2004; 147:919-923
26. Berghoff M, Kathpal M, Khan F, Skinner M, Falk R, Freeman R. Endothelial dysfunction precedes C-fiber abnormalities in primary (AL) amyloidosis. Ann Neurol 2003; 53:725-730
27. Khan MF, Falk RH. Amyloidosis. Postgrad Med J 2001; 77:686-693
28. Martinez-Naharro A, Treibel TA, Abdel-Gadir A, et al. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol 2017; 70:466-477
29. Longhi S, Quarta CC, Milandri A, et al. Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role. Amyloid 2015; 22:147-155
30. Sperry BW, Vranian MN, Hachamovitch R, et al. Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. Int J Cardiol 2016; 214:477-481
31. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112:2047-2060
32. Berk JL, Keane J, Seldin DC, et al. Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis. Chest 2003; 124:969-977
33. Miani D, Rocco M, Alberti E, Spedicato L, Fioretti PM. Amyloidosis of epicardial and intramural coronary arteries as an unusual cause of myocardial infarction and refractory angina pectoris. Ital Heart J 2002; 3:479-482
34. Mesquita ET, Jorge AJL, Souza CV Junior, Andrade TR. Cardiac amyloidosis and its new clinical phenotype: heart failure with preserved ejection fraction. Arg Bras Cardiol 2017; 109:71-80
35. Swanton RH, Brooksby IAB, Davies MJ, Coltart DJ, Jenkins BS, Webb-Peploe MM. Systolic and diastolic ventricular function in cardiac amyloidosis: studies in six cases diagnosed with endomyocardial biopsy. Am J Cardiol 1977; 39:658-664
36. Tyberg TI, Goodyer AVN, Hurst VW 3rd, Alexander J, Langou RA. Left ventricular filling in differentiating restrictive amyloid cardiomyopathy and constrictive pericarditis. Am J Cardiol 1981; 47:791-796
37. Sperry BW, Jones BM, Vranian MN, Hanna M, Jaber WA. Recognizing transthyretin cardiac amyloidosis in patients with aortic stenosis: impact on prognosis. JACC Cardiovasc Imaging 2016; 9:904-906
38. Cyrille NB, Goldsmith J, Alvarez J, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol 2014; 114:1089-1093
39. Hongo M, Yamamoto H, Kohda T, et al. Comparison of electrocardiographic findings in patients with AL (primary) amyloidosis and in familial amyloid polyneuropathy and anginal pain and their relation to histopathologic findings. Am J Cardiol 2000; 85:849-853
40. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 2017; 135:1357-1377
41. Abdalla I, Murray RD, Lee JC, Stewart WJ, Tajik AJ, Klein AL. Duration of pulmonary venous atrial reversal flow velocity and mitral inflow a wave: new measure of severity of cardiac amyloidosis. J Am Soc Echocardiogr 1998; 11:1125-1133
42. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016; 133:2404-2412
43. Gertz MA. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Am J Hematol 2016; 91:947-956
44. Patel KS, Hawkins PN. Cardiac amyloidosis: where are we today? J Intern Med 2015; 278:126-144
45. Ritts AJ, Cornell RF, Swiger K, Singh J, Goodman S, Lenihan DJ. Current concepts of cardiac amyloidosis: diagnosis, clinical management, and the need for collaboration. Heart Fail Clin 2017; 13:409-416
46. Sperry BW, Vranian MN, Hachamovitch R, et al. Subtype-specific interactions and prognosis in cardiac amyloidosis. J Am Heart Assoc 2016; 5:e002877
47. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30:989-995
48. Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012; 98:1442-1448
49. Patel AR, Kramer CM. Role of cardiac magnetic resonance in the diagnosis and prognosis of nonischemic cardiomyopathy. JACC Cardiovasc Imaging 2017; 10(10 Pt A):1180-1193
50. White JA, Kim HW, Shah D, et al. CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis. JACC Cardiovasc Imaging 2014; 7:143-156
51. Parkey RW, Bonte FJ, Meyer SL, et al. A new method for radionuclide imaging of acute myocardial infarction in humans. Circulation 1974; 50:540-546
52. Wizenberg TA, Muz J, Sohn YH, Samlowski W, Weissler AM. Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis. Am Heart J 1982; 103(4 Pt 1):468-473
53. Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. 99mTc-Pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013; 6:195-201
54. Vranian MN, Sperry BW, Hanna M, et al. Technetium pyrophosphate uptake in transthyretin cardiac amyloidosis: associations with echocardiographic disease severity and outcomes. J Nucl Cardiol 2017; Jan 3. [Epub ahead of print] doi: 10.1007/s12350-016-0768-9
55. Bennett MK, Gilotra NA, Harrington C, et al. Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000-2009. Circ Heart Fail 2013; 6:676-684
56. Garcia Y, Collins AB, Stone JR. Abdominal fat pad excisional biopsy for the diagnosis and typing of systemic amyloidosis. Hum Pathol 2017; Nov 10. [Epub ahead of print] doi:10.1016/j.humpath.2017.11.001
57. Quarta CC, Gonzalez-Lopez E, Gilbertson JA, et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J 2017; 38:1905-1908
58. Fine NM, Arruda-Olson AM, Dispenzieri A, et al. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol 2014; 113:1723-1727
59. Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 2005; 51:878-781
60. Malha L, Mann SJ. Loop diuretics in the treatment of hypertension. Curr Hypertens Rep 2016; 18:27
61. Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation 1981; 63:1285-1288
62. Feng D, Syed IS, Martinez M, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 2009; 119:2490-2497
63. Castaño A, Drachman BM, Judge D, Maurer MS. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev 2015; 20:163-178
64. Hamon D, Algalarrondo V, Gandjbakhch E, et al. Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis. Int J Cardiol 2016; 222:562-568
65. Patel KS, Hawkins PN, Whelan CJ, Gillmore JD. Life-saving implantable cardioverter defibrillator therapy in cardiac AL amyloidosis. BMJ Case Rep 2014; Dec 22. doi:10.1136/bcr-2014-206600
66. Gertz M, Lacy M, Dispenzieri A, et al. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma 2008; 49:36-41
67. Vranian MN, Sperry BW, Valent J, Hanna M. Emerging advances in the management of cardiac amyloidosis. Curr Cardiol Rep 2015; 17:100
68. Alexander KM, Singh A, Falk RH. Novel pharmacotherapies for cardiac amyloidosis. Pharmacol Ther 2017; 180:129-138
69. Sher T, Fenton B, Akhtar A, Gertz MA. First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis. Blood 2016; 128:1987-1989
70. Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood 2017; 130:597-605
71. Zumbo G, Sadeghi-Alavijeh O, Hawkins PN, Fontana M. New and developing therapies for AL amyloidosis. Expert Opin Pharmacother 2017; 18:139-149
72. Koyama J, Falk RH. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging 2010; 3:333-342
73. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012; 30:4541-4549
74. Sousa M, Monohan G, Rajagopalan N, Grigorian A. Heart transplantation in cardiac amyloidosis. Heart Fail Rev 2017; 22:317-327
75. Gertz MA, Landau H, Comenzo RL, et al. First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol 2016; 34:1097-1103
76. Holmgren G, Steen L, Ekstedt J, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 1991; 40:242-246
77. Hanna M. Novel drugs targeting transthyretin amyloidosis. Curr Heart Fail Rep 2014; 11:50-57
78. Berk JL, Suhr OB, Obici L, et al; Diflunisal Trial Consortium. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013; 310:2658-2667
79. Castaño A, Helmke S, Alvarez J, Delisle S, Maurer MS. Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail 2012; 18:315-319
80. Sekijima Y, Tojo K, Morita H, Koyama J, Ikeda S-I. Safety and effi-cacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid 2015; 22:79-83
81. Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012; 79:785-792
82. Maurer MS, Grogan DR, Judge DP, et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail 2015; 8:519-526
83. Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ. Synergy of combined doxycycline/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med 2010; 8:74
84. Obici L, Cortese A, Lozza A, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: A phase II study. Amyloid 2012; 19(suppl 1):34-36
85. Kristen AV, Lehrke S, Buss S, et al. Green tea halts progression of cardiac transthyretin amyloidosis: An observational report. Clin Res Cardiol 2012; 101:805-813
86. Higaki JN, Chakrabartty A, Galant NJ, et al. Novel conformationspecifi c monoclonal antibodies against amyloidogenic forms of forms of transthyretin. Amyloid 2016; 23:86-97